FDA BLA for Sanfilippo Drug on Track for Q4 2026; Spruce Biosciences Secures $50M Capital
Summary
Spruce Biosciences announced significant corporate updates, including securing up to $50 million in growth capital from Avenue Capital Group, with an initial $15 million already funded. The company also reported positive Type B meetings with the FDA, confirming the Biologics License Application (BLA) submission for its lead drug, TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB), is on track for Q4 2026. The FDA indicated that integrated study data could support accelerated approval. Additionally, the company appointed Dale Hooks as Chief Commercial Officer and presented positive long-term data for TA-ERT. Full year 2025 financial results were reported, but specific figures were not detailed in the provided content. The $50 million financing is highly material for a company with a market cap of approximately $60 million, significantly bolstering its financial runway and supporting the commercial launch of TA-ERT. The positive FDA feedback and clear BLA timeline de-risk the regulatory path for TA-ERT, which targets a disease with no approved therapies. The appointment of a Chief Commercial Officer and other executives further signals the company's readiness for commercialization. Investors will now focus on the successful BLA submission in Q4 2026 and the subsequent FDA review process, as well as the company's progress in building out its commercial infrastructure.
At the time of this announcement, SPRB was trading at $58.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $59.8M. The 52-week trading range was $4.28 to $240.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.